A busy morning of corporate news spanned deal completions, clinical fundraises, and operational updates across the small- and mid-cap universe. Sound Energy (AIM:SOU)'s exit from Morocco headlined the session, while CVS Group (AIM:CVSG) combined a debt refinancing with a fresh buyback and an Australian acquisition, and Arrow Exploration (AIM:AXL) confirmed a material Colombian discovery.
Sound Energy exits Morocco with US$57m Tendrara sale
Sound Energy (AIM:SOU) has agreed to sell its remaining stake in the Tendrara gas project to Managem for US$57m, a transaction the company described as crystallising significant shareholder value while leaving it debt-free and positioned to redeploy capital into energy transition opportunities. Chief Executive Majid Shafiq called it a transformational milestone. The shares eased 2.9% to 4.7p, a move that likely reflects investors taking profits on a long-running asset disposal rather than any negative read on the deal itself.
CVS Group refinances debt, launches £50m buyback, and acquires Sydney practice
CVS Group (AIM:CVSG) announced a trio of capital-allocation moves: a refinancing of its £350m bank facilities on improved terms, approval of a £50m share buyback programme, and the agreed acquisition of a single-site small-animal practice in Sydney for approximately A$8.2m (c.£4m). The combination of lower borrowing costs, a meaningful return of capital, and continued bolt-on expansion in Australia was well received, with the shares adding 0.84% to 1,199p. Chief Executive Richard Fairman has signalled that the refinancing creates headroom for further strategic investment.
Arrow Exploration confirms material discovery at Icaco-1
Arrow Exploration (AIM:AXL) brought the Icaco-1 well onstream at approximately 628 barrels of oil per day gross on the Tapir Block in Colombia, with CEO Marshall Abbott describing the result as a material discovery in the southeastern area of the block. The well's initial flow rate drove the shares up 8% to 23.5p, extending Arrow's run of successful Tapir drilling.
AstraZeneca wins CHMP backing for tumour-agnostic Enhertu label
AstraZeneca (LSE:AZN) received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for Enhertu, developed with Daiichi Sankyo, covering previously treated HER2-positive (IHC 3+) unresectable or metastatic solid tumours regardless of origin. The approval, if confirmed by the European Commission, would make Enhertu the first HER2-directed therapy to receive a tumour-agnostic indication in Europe, a significant commercial and scientific milestone. The shares slipped 0.64% to 13,916p, with the CHMP opinion having been widely anticipated. Susan Galbraith, who leads oncology R&D at the company, has been central to the programme's development.
Atalaya reiterates full-year guidance after rain-hit Q1
Atalaya Mining (AIM:ATYM) reported Q1 copper production of 9,939 tonnes, sharply below the 14,291 tonnes produced in the same period a year earlier, with heavy rainfall at the Proyecto Riotinto operation in Spain cited as the primary cause. Despite the shortfall, the company reiterated its full-year 2026 guidance of 50,000-54,000 tonnes, implying a significant recovery in output through the remainder of the year. The shares dipped 0.88% to 789.5p.
Kingfisher reports resilient Q1 trading in line with guidance
Kingfisher (LSE:KGF) said first-quarter trading was on track to meet its FY2026/27 guidance, with CEO Thierry Garnier noting the group had gained market share against a soft market backdrop. The update provided no grounds for a guidance revision in either direction, and the shares were little changed, off 0.41% at 292.2p.
CRISM Therapeutics raises £2.5m for glioblastoma Phase 2 trial
Crism Therapeutics Corporation (AIM:CRTX) completed an oversubscribed placing raising £2.5m to fund its Phase 2 irinotecan-ChemoSeed trial in glioblastoma and to support pursuit of grant funding. The oversubscription underlined investor appetite for the programme, and the shares jumped 10.6% to 13.0p.
PipeHawk clears NSI Act review on Utsi Electronics sale
PipeHawk (AIM:PIP) received confirmation from the Cabinet Office that it will not take further action under the National Security and Investment Act in relation to the proposed disposal of Utsi Electronics, removing a key regulatory hurdle for the transaction. The shares were quoted at 2.75p.
Georgina Energy begins pre-drill civil works at Hussar
Georgina Energy (AIM:GEX) has started civil-engineering pre-drill works at the Hussar prospect within EP513 in Australia's Northern Territory, following the contracting of an Ensign 970 drill rig. The well is designed to target subsalt reservoirs carrying independently assessed 2U recoverable resources. The shares eased 1.59% to 6.2p.
Helix begins Inez #1 re-entry at Rudyard helium project
Helix Exploration (AIM:HEX) rigged up and commenced re-entry operations at the Inez #1 well at its Rudyard project in Montana, targeting the Souris River interval for near-term helium production. The shares edged up 1.1% to 40.5p. CEO Bo Sears has positioned the re-entry as a low-cost route to establishing initial cash flow from the project.
ProBiotix Health secures exclusive Iberian supply deal with Bioksan
ProBiotix Health signed an exclusive supply agreement with Spain-based Bioksan to provide its patented LPLDL® probiotic strain for reformulation of the Lipok® cardiovascular supplement across Spain and Portugal. The partnership is expected to generate approximately €200,000 per year in ProBiotix sales, extending the commercial reach of its flagship strain into the Iberian market.
GEO Exploration advances 2026 Gorge programme with airborne surveys
GEO Exploration (AIM:GEO) has begun its 2026 work programme at the Gorge Project in Western Australia, completing a high-resolution LiDAR and aerial photography survey ahead of schedule and commencing airborne magnetic and radiometric surveys. The data will be used to focus maiden drilling targets. The shares were quoted at 0.1125p.
Diaceutics returns to profit with 80% EBITDA growth
Diaceutics reported a return to profitability alongside an 80% rise in adjusted EBITDA, with CEO Ryan Keeling attributing the performance to the resilience of the company's platform model and rising demand for diagnostic intelligence in precision medicine. The results reflect growing adoption of Diaceutics' data services by pharmaceutical customers seeking to improve patient identification and therapy uptake.
